GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
The Coinbase CEO-backed longevity company will advance its epigenetic reprogramming mRNA medicine into Phase I trials for fatty …
The Alphabet-backed spinout of DeepMind’s AlphaFold programme has raised the largest private financing round in AI drug discovery …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to …
The British pharma giant’s third major deal of 2026 secures two FDA Breakthrough Therapy-designated kinase inhibitors and a …
The stealth-mode startup emerges with a pipeline targeting focal epilepsy, schizophrenia, tinnitus, and reversible encephalopathy — all acquired …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
MaaT Pharma advances its microbiome ecosystem therapies with new preclinical evidence showing enhanced patient immunotherapy responses.
MaaT Pharma strengthens financial position to advance its microbiome-based therapies, focusing on acute graft-versus-host disease and hemato-oncology indications.
Already a subscriber? Log in